Q-omics provides the consensus-scored ASH2LP3 profile across patient tissues and cancer cell-line models. ASH2LP3 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in DLBC. Among the 18 cancer types available for tumor–normal comparison, ASH2LP3 is differentially expressed in 6, with the highest sampling consensus in BRCA. Additionally, ASH2LP3 RNA expression shows 10,540 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight DLBC, BRCA, and TGCT as cancer lineages where ASH2LP3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ASH2LP3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ASH2LP3 survival associations across molecular data types. ASH2LP3 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ASH2LP3 RNA expression–survival associations across cancer types. High ASH2LP3 expression shows unfavorable associations in DLBC, STAD, PRAD and MESO, but favorable associations in CESC and UVM. The DLBC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify DLBC as the clearest survival context for ASH2LP3 RNA expression.
This table summarizes ASH2LP3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for ASH2LP3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ASH2LP3 shows lower tumor expression in KICH, PAAD and THCA and higher tumor expression in BRCA, CHOL and LIHC. The BRCA box plot shows higher ASH2LP3 RNA expression in tumor versus normal tissue (log2 FC = +0.050, t-test p = .028).
This table shows molecular features associated with ASH2LP3 in patient tissues and cancer cell lines. In patient samples, ASH2LP3 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
